Cytokinetics Incorporated
Last updated September 27, 2026
Organization details
- Legal name
- Cytokinetics Incorporated
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CYTK
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001061983
Board of directors
-
B. Lynne Parshall · DirectorSince 2023
-
Edward M. Kaye M.D. · DirectorSince 2023
-
James M. Daly · DirectorSince 2025
-
John T. Henderson · DirectorSince 2023
-
Muna Bhanji · DirectorSince 2023
-
Nancy Wysenski · DirectorSince 2023
-
Robert Arthur Harrington · DirectorSince 2023
-
Robert E. Landry · DirectorSince 2025
-
Robert I. Blum · Director · President & CEOSince 2023
-
Sandford D. Smith · DirectorSince 2023
-
Santo J. Costa · DirectorSince 2023
-
Wendall Wierenga · DirectorSince 2023
-
Wendell Wierenga · DirectorSince 2025
Chief executives
Robert I. Blum
· President & CEO
Dates unknown
Board connections
8 of this board's directors also sit on 13 other boards.
- via James M. Daly
- via Nancy Wysenski
- via Santo J. Costa
- via Muna Bhanji
- via Wendell Wierenga
- via B. Lynne Parshall
- via James M. Daly
- via Muna Bhanji
- via B. Lynne Parshall
- via James M. Daly
- via Edward M. Kaye M.D.
- via Muna Bhanji
- via Robert E. Landry
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $52,263,074
- 88 sales by 10 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Fady Ibraham Malik Officer (EVP Research & Development) | Option exercise | +3,500 | $7.80 | $27,300 |
| Sep 22, 2026 | Fady Ibraham Malik Officer (EVP Research & Development) | Open-market sale | −3,500 | $68.29 | $239,015 |
| Sep 15, 2026 | Robert E. Landry Director | Open-market sale | −1,000 | $72.13 | $72,130 |
| Sep 15, 2026 | Robert I. Blum Director, Officer (President & CEO) | Open-market sale | −97,926 | $69.33 | $6,789,210 |
| Sep 14, 2026 | Robert I. Blum Director, Officer (President & CEO) | Option exercise | +7,500 | $10.60 | $79,500 |
| Sep 14, 2026 | Robert I. Blum Director, Officer (President & CEO) | Open-market sale | −7,500 | $73.44 | $550,800 |
| Sep 14, 2026 | Robert I. Blum Director, Officer (President & CEO) | Gift | −1,350 | — | — |
| Sep 14, 2026 | Robert I. Blum Director, Officer (President & CEO) | Gift | −97,926 | — | — |
| Sep 14, 2026 | Robert I. Blum Director, Officer (President & CEO) | Gift | +97,926 | — | — |
| Sep 11, 2026 | Robert E. Landry Director | Open-market sale | −1,000 | $74.66 | $74,660 |
| Sep 8, 2026 | Fady Ibraham Malik Officer (EVP Research & Development) | Option exercise | +3,500 | $7.80 | $27,300 |
| Sep 8, 2026 | Fady Ibraham Malik Officer (EVP Research & Development) | Open-market sale | −3,500 | $75.46 | $264,110 |
| Sep 1, 2026 | B. Lynne Parshall Director | Open-market sale | −5,000 | $71.48 | $357,400 |
| Aug 31, 2026 | Robert I. Blum Director, Officer (President & CEO) | Option exercise | +7,500 | $10.60 | $79,500 |
| Aug 31, 2026 | Callos Andrew Officer (EVP, Chief Commercial Officer) | Option exercise | +10,000 | $23.26 | $232,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.